240.30EUR+0.50%Mkt Cap: 45.12B EURP/E: 29.51Last update: 2026-05-14
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)29.51
P/E (Forward)17.43
PEG1.79
P/B4.15
P/S5.83
EV/EBITDA17.21
EV/Revenue5.81
EPS (TTM)8.03
EPS (Forward)13.59
Cash Flow & Leverage
FCF Yield4.05%
FCF Margin23.59%
Operating CF2.29B EUR
CapEx (TTM)449.00M EUR
Net Debt/EBITDA-0.05
Net Debt-118.00M EUR
Technical
SMA 50250.85 (-4.2%)
SMA 200239.63 (+0.3%)
Beta0.17
S&P 52W Chg24.23%
Avg Vol (30d)262.42K
Avg Vol (10d)196.19K
Technical Indicators
RSI (14)46.7
MACD-4.9458
MACD Signal-6.0777
MACD Hist.+1.1319
BB Upper261.20 EUR
BB Middle239.99 EUR
BB Lower218.77 EUR
BB Width17.68%
ATR (14)6.932 EUR
Vol Ratio (20d)0.57x
52W Range
152.9564% of range289.50
52W High289.50 EUR
52W Low152.95 EUR
Profitability
Gross Margin74.29%
EBITDA Margin33.77%
Profit Margin20.13%
Oper. Margin30.39%
ROE14.34%
ROA8.58%
Revenue Growth26.60%
Earnings Growth26.30%
Balance Sheet
Debt/Equity0.21
Current Ratio1.38
Quick Ratio0.94
Book Value/Sh57.09 EUR
Cash/Share12.41 EUR
Dividends
Fwd Div Rate1.450 EUR
Trail. Div Rate1.450 EUR
Div. Yield0.61%
5Y Avg Yield1.21%
Payout Ratio17.31%
Ex-Div DateMay 4, 2026
Pay Date—
Ownership
Shares Out.190.36M
Float119.86M
Insiders36.28%
Institutions41.08%
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)288.21 EUR
Target Range195.00 EUR – 340.00 EUR
# Analysts19
Company
Market Cap45.12B EUR
Enterprise Value45.00B EUR
Revenue (TTM)7.74B EUR
Gross Profit5.75B EUR
Net Income (TTM)1.56B EUR
Revenue/Share40.72 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees9.8K
Last Price240.30 EUR
CountryBE
SectorHealthcare
IndustryBiotechnology
ISIN—